Anagenics stock analysis
Want to see AU:AN1 full AI Analyst Report?
Anagenics (AN1) Share Price & Analysis
AN1 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- AUD 5.96M
- Enterprise Value
- AUD 6.04M
- Total Cash (Recent Filing)
- AUD 577.43K
- Total Debt (Recent Filing)
- AUD 33.19K
- Price to Earnings (P/E)
- 15.0
- Beta
- 1.27
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Return To Profitability
The return to positive operating and net profit marks a meaningful earnings inflection after several loss-making years. If management sustains this improvement, stronger internal earnings can support reinvestment, improve resilience, and establish a more durable base for future growth.
Very Low Leverage
Very low leverage reduces interest and refinancing pressure while preserving financial flexibility. A positive, substantial equity base gives Anagenics more capacity to manage operating volatility, fund strategic initiatives, and withstand periods when trading performance or cash generation weakens.
Improved Gross Margin
A sharp gross-margin improvement can strengthen the economics of the Hair Again product portfolio and provide greater operating leverage as sales develop. Sustaining better margins would make the recent return to profitability more credible and improve the company’s ability to convert revenue into earnings.
Bears Say
Negative Cash Generation
Persistent negative operating and free cash flow means reported profitability has not yet translated into self-funded operations. Continued cash burn can require use of balance-sheet resources or external capital, limiting strategic flexibility and making the recovery more vulnerable if conditions weaken.
Revenue Below Prior Peak
Revenue below the 2024 peak indicates that the earnings recovery is occurring without a clear restoration of the company’s previous sales scale. A smaller revenue base can constrain operating leverage, reduce growth opportunities, and leave profitability more sensitive to changes in product demand.
Unproven Earnings Consistency
The long sequence of losses and volatile margins makes the latest profitable period less proven as a durable trend. Until positive earnings are repeated across future reporting periods, investors face uncertainty over whether the improvement reflects a sustainable business reset or a temporary recovery in performance.
Anagenics News
AN1 FAQ
What is Anagenics ’s market cap?
When is Anagenics ’s upcoming earnings report date?
How were Anagenics ’s earnings last quarter?
Is Anagenics overvalued?
Does Anagenics pay dividends?
What is Anagenics ’s EPS estimate?
How many shares outstanding does Anagenics have?
What happened to Anagenics ’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Anagenics ?
What is the TipRanks Smart Score and how is it calculated?
Anagenics Stock Smart Score
Company Description
Anagenics
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
- Sector
- Consumerdefensive
- Industry
- Household & Personal Products
- CEO
- Chris Lewis
- Employees
- 11
- Website
- anagenics.com
- Address
- 55 Clarence Street, Sydney, NSW, 2000, AU








